Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes

Erythrocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) contained a subpopulation that lacked membrane-associated Factor H-like activity present on normal human erythrocytes. Initial deposition of C3b on the erythrocytes was effected using a fluid phase C3 convertase. The cells were then treated with fluorescein-labeled C3 and the cell-bound C3 convertase. Analysis utilizing the fluorescence- activated cell sorter revealed two distinct cell populations, one of which was highly fluorescent, indicating a large number of C3b molecules per cell. Only this population (43%) was susceptible to lysis (44%) when exposed to acidified serum before C3b deposition. The less fluorescent population resembled normal human erythrocytes and was not affected by prior treatment with acidified serum. Since C3b deposition occurred almost exclusively on the complement-sensitive cells in the PNH erythrocyte population, these cells could be examined for the Factor H-like regulatory activities without prior isolation. These functions include enhancement of inactivation of erythrocyte-bound C3b by Factor I and acceleration of the decay of erythrocyte-bound C3 convertase, C3b,Bb. It was found that C3b on PNH erythrocytes was 100- fold less susceptible to inactivation by Factor I than C3b on normal human erythrocytes. The half-life at 22 degrees C of C3b,Bb on PNH erythrocytes was threefold greater than on normal human erythrocytes and similar to that of the enzyme bound to particles that do not possess Factor H-like activity. These observations suggest that the abnormal susceptibility of PNH erythrocytes to lysis by complement is due to a functional deficiency in one or more of the Factor H-like proteins present on normal human erythrocytes.

[1]  J. Dacie,et al.  The influence of pH on in‐vitro hæmolysis in nocturnal hæmoglobinuria , 1943 .

[2]  W. S. Jordan,et al.  The properdin system and immunity. IV. The hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria. , 1956, The Journal of clinical investigation.

[3]  E. M. Hoffman Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata. , 1969, Immunochemistry.

[4]  C. Cochrane,et al.  Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. , 1969, Journal of immunology.

[5]  E. M. Hoffmann,et al.  Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action. , 1969, Immunochemistry.

[6]  O. Götze,et al.  LYSIS OF ERYTHROCYTES BY COMPLEMENT IN THE ABSENCE OF ANTIBODY , 1970, The Journal of experimental medicine.

[7]  O. Götze,et al.  THE C3-ACTIVATOR SYSTEM: AN ALTERNATE PATHWAY OF COMPLEMENT ACTIVATION , 1971, The Journal of experimental medicine.

[8]  O. Götze,et al.  Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system. , 1972, The New England journal of medicine.

[9]  O. Götze,et al.  C3 PROACTIVATOR CONVERTASE AND ITS MODE OF ACTION , 1972, The Journal of experimental medicine.

[10]  O. Götze,et al.  Paroxysmal Nocturnal Hemoglobinuria , 1972 .

[11]  R. Schreiber,et al.  Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor , 1975, The Journal of experimental medicine.

[12]  R. Schreiber,et al.  Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution , 1977, The Journal of experimental medicine.

[13]  Ross Wf Paroxysmal nocturnal haemoglobinuria in aplastic anaemia. , 1978 .

[14]  M. Pangburn,et al.  Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[15]  W. Rosse Paroxysmal nocturnal haemoglobinuria in aplastic anaemia. , 1978, Clinics in haematology.

[16]  D. Fearon,et al.  Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Frank,et al.  Studies of the molecular mechanisms of C3b inactivation and a simplified assay of beta 1H and the C3b inactivator (C3bINA). , 1979, Journal of immunology.

[18]  H. Müller-Eberhard,et al.  The alternative pathway C3/C5 convertase: chemical basis of factor B activation. , 1979, Journal of immunology.

[19]  M. Pangburn,et al.  Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement , 1980, The Journal of experimental medicine.

[20]  R. Schreiber,et al.  Molecular biology and chemistry of the alternative pathway of complement. , 1980, Advances in immunology.

[21]  D. Fearon Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte , 1980, The Journal of experimental medicine.

[22]  H. Gresham,et al.  Large scale isolation of functionally active components of the human complement system. , 1981, The Journal of biological chemistry.

[23]  R. Schreiber,et al.  Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3 , 1981, The Journal of experimental medicine.

[24]  V. Nussenzweig,et al.  Complement receptor is an inhibitor of the complement cascade , 1981, The Journal of experimental medicine.

[25]  H. Colten,et al.  Characterization of the human complement (c3b) receptor with a fluid phase C3b dimer. , 1981, Journal of immunology.

[26]  C. Mold,et al.  Release of soluble immune complexes from immune adherence receptors on human erythrocytes is mediated by C3b inactivator independently of Beta 1H and is accompanied by generation of C3c. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Baker,et al.  Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria. , 1982, The Journal of clinical investigation.

[28]  M. Daha,et al.  Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor. , 1982, Clinical and experimental immunology.

[29]  J. Lambris,et al.  Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. , 1982, Journal of immunology.

[30]  H. Müller-Eberhard,et al.  The cobra venom factor-dependent C3 convertase of human complement. A kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate. , 1982, The Journal of biological chemistry.

[31]  M. Arnaout,et al.  Release of C3c from bound C3bi by C3b inactivator , 1982 .

[32]  P. Schur,et al.  Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. , 1982, The New England journal of medicine.

[33]  J. Oger,et al.  Kinetics of interaction of immune complexes with complement receptors on human blood cells: modification of complexes during interaction with red cells. , 1982, Clinical and experimental immunology.

[34]  D. Fearon,et al.  Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. , 1982, Journal of immunology.

[35]  M. Pangburn Activation of complement via the alternative pathway. , 1983, Federation proceedings.

[36]  Pang Mk Activation of complement via the alternative pathway. , 1983 .